Ms200095-0022- A Phase II Single-Arm Trial To Investigate Tepotinib In Stage IIIb/Iv Adenocarcinoma Of The Lung With Met Exon 14 (Metex14) Skipping Alterations After Failure Of At Least One Prior Active Therapy, Including A Platinum-Doublet-Containing Reg
Posted Date: May 15, 2019
- Investigator: John Morris
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to learn how effective the study drug, tepotinib, is at stopping the growth and spread of lung cancer that did not respond to previous treatment with a specific type of chemotherapy. This study will also measure the safety of the study drug and the side effects.
Criteria:
To Be Eligible: Must Have Confirmed Stage Iiib/Iv Nsclc, Age 18 Or Older, Nonpregnant And Nonbreastfeeding, No Prior Chemo, Radiation Or Hormonal Therapy Within 21 Days
Keywords:
Lung Cancer, Adenocarcinoma, Cancer, Phase Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com